Holen Sie sich die Stockscreener-App
0.709
1.29%
0.009
Handel nachbörslich:
.68
-0.029
-4.09%
Schlusskurs vom Vortag:
$0.70
Offen:
$0.73
24-Stunden-Volumen:
76,876
Relative Volume:
0.78
Marktkapitalisierung:
$7.38M
Einnahmen:
$3.95M
Nettoeinkommen (Verlust:
$-14.59M
KGV:
-0.6098
EPS:
-1.1626
Netto-Cashflow:
$-14.46M
1W Leistung:
-4.70%
1M Leistung:
-10.03%
6M Leistung:
-37.53%
1J Leistung:
-39.40%
1-Tages-Spanne:
$0.68
$0.7361
1-Wochen-Bereich:
$0.66
$0.7654
52-Wochen-Spanne:
$0.66
$2.42
Evogene Ltd Stock (EVGN) Company Profile
Compare EVGN vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EVGN
Evogene Ltd
|
0.709 | 7.29M | 3.95M | -14.59M | -14.46M | -1.1626 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Evogene Ltd Stock (EVGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-10-08 | Eingeleitet | ROTH Capital | Buy |
| 2021-07-29 | Eingeleitet | Aegis Capital | Buy |
| 2020-12-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2013-12-16 | Eingeleitet | Oppenheimer | Outperform |
Evogene Ltd Aktie (EVGN) Neueste Nachrichten
Evogene shares decline after revenue miss despite stronger-than-expected earnings (EVGN) - MSN
Evogene Q1 2026 earnings preview - MSN
Evogene Ltd. (NASDAQ:EVGN) Q1 2026 Earnings Call Transcript - Insider Monkey
Evogene Reports First Quarter 2026 Financial Results - Dailyhunt
Evogene Ltd stock (IL0010831684): Q1 revenue slump highlights high?risk transformation phase - AD HOC NEWS
Evogene stock falls 5% on revenue miss despite earnings beat - Investing.com
Evogene Earnings Call: AI Momentum vs. Cash Strain - TipRanks
Evogene earnings beat by $0.26, revenue fell short of estimates - Investing.com Australia
Evogene Q1 2026 Loss Deepens: -$0.60/Share vs -$0.28 Expected - AlphaStreet
EVGN: Revenue fell sharply and net loss widened as focus shifted to core AI-driven pharma and ag chem - TradingView
Earnings call transcript: Evogene reports Q1 2026 loss, stock rises 1.95% - Investing.com Australia
EVGN: AI-driven pharma and ag chemical focus advances, but Q1 revenue drops and net loss widens - TradingView
Evogene Ltd. Q1 2026 Earnings Call Summary - Yahoo Finance
Evogene Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Evogene reports Q1 results: net loss widens amid revenue decline - grafa.com
Evogene Shares Decline After Revenue Miss Despite Stronger-Than-Expected Earnings (EVGN) - Yahoo Finance
Evogene Ltd reports results for the quarter ended March 31Earnings Summary - TradingView
Evogene Ltd files for offering of 2.45 million ordinary shares by selling shareholder SEC filing - marketscreener.com
Evogene 1Q Loss/Shr 60c >EVGN.TV - Moomoo
Evogene Ltd Files For Offering Of 2.45 Million Ordinary Shares By Selling Shareholder SEC Filing - TradingView
Evogene (NASDAQ: EVGN) registers 2.45M shares for resale, files Q1 2026 results - Stock Titan
Evogene Tightens Focus on AI Small-Molecule Platform as Q1 2026 Revenue Falls - TipRanks
Evogene : Q1 2026 Consolidated Financial Statements - marketscreener.com
EVOGENE ($EVGN) Releases Q1 2026 Earnings - Quiver Quantitative
Evogene stock falls 5% on revenue miss despite earnings beat By Investing.com - Investing.com Australia
EVGN: Q1 2026 revenue declined and net loss widened, but AI-driven pipeline and partnerships advanced - TradingView
Evogene: Q1 Earnings Snapshot - marketscreener.com
Evogene (EVGN) Q1 2026 shows sharp revenue fall, wider loss and cash burn - Stock Titan
Press Release: Evogene Reports First Quarter 2026 Financial Results - Moomoo
Evogene Q1 2026 Earnings Call Transcript - MarketBeat
EVGN Q1'26 Earnings: EPS estimate is (0.27) USD - TradingView
Evogene’s Ag Plenus, Bayer End Herbicide Collaboration as APTH1 Target Falls Short - TipRanks
Evogene (EVGN) and Bayer terminate herbicide project, APTH1 assets return to AgPlenus - Stock Titan
Evogene Ltd expected to post a loss of 27 cents a shareEarnings Preview - TradingView
Evogene Ltd stock (IL0010831684): AI-driven biotech draws attention after recent financing update - AD HOC NEWS
Evogene Ltd.Ordinary Shares (NQ: EVGN - The Chronicle-Journal
Armistice Capital and Steven Boyd report 9.99% of EVGN (May 2026) - Stock Titan
Earnings Preview: Evogene to Report Financial Results Pre-market on May 20 - Moomoo
Evogene (EVGN) Institutional Ownership 2026 - MarketBeat
Evogene Ltd stock (IL0010831684): recent financing move and pipeline focus draw investor attention - AD HOC NEWS
AI-designed drug molecules: Evogene presents GenAI model in Munich - Stock Titan
Evogene to Present at the 24th Schrödinger European User Group Meeting - marketscreener.com
TradingKey - TradingKey
Evogene will discuss first-quarter results on a May 20 Zoom call - Stock Titan
Evogene Schedules First Quarter 2026 Financial Results Release - Barchart.com
Genetically Modified Seeds Market 2026 Growth, Industry - openPR.com
Evogene receives Nasdaq notification - MSN
Evogene files for resale of 5.08M shares via warrant exercise - MSN
Finanzdaten der Evogene Ltd-Aktie (EVGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):